Once-rival researchers from the Fred Hutchinson Cancer Research Center and Memorial Sloan-Kettering Cancer Center have decided to join forces and dive into drug development, hauling in a massive $120 million Series A round to advance "smart" T cells that spur an immunologic attack on cancers.
Veteran biotech exec Jack Talley has stepped into the top job at Actinium Pharmaceuticals, a low-profile developer which has been pursuing a lengthy effort to develop an armed antibody that can be used to fight blood cancers.
A recent study published in the Journal of Infectious Disease confirmed that a vaccine study halted in 2007 showed an increased risk of infection in the first 18 months for subgroups of the men who were vaccinated, but that this difference disappeared after 18 months.
Prostate cancer is very common, but it is often slow growing and symptom-free. So, for many men, the best policy is 'watch and wait'. However, a proportion of prostate cancers turn out to be
The National Cancer Institute is funneling $17 million to the renowned Fred Hutchinson Cancer Research Center in Seattle to pay for new discovery work on fresh cancer biomarkers along with